Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
Plexiform neurofibromas (PN) are known to cause significant morbidity in children with NF1. The recent FDA approval for selumetinib in children 2 years and older with inoperable symptomatic PN was bas...
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
This is a two-staged, Phase 2/3, randomized, multi-center study to investigate the efficacy and safety of REC-2282 in patients with progressive NF2 mutated meningiomas....
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
The trial will be an open label, single arm, phase 2 study in 20 participants. The study will assess the tolerability and efficacy of HLX-1502 in participants with NF1 16 years of age or older with pr...
Top Cities for Neurofibromatosis Clinical Trials
Neurofibromatosis clinical trials are recruiting across 15 cities. Here are the cities with the most active studies:
About Neurofibromatosis
Neurofibromatosis is a group of genetic conditions that cause tumors to grow on nerve tissue. NF1 is the most common type, causing skin changes and bone deformities. Treatment includes monitoring, surgery for problematic tumors, and MEK inhibitors for plexiform neurofibromas.
Clinical trials are advancing new treatments for neurofibromatosis. Currently, 3 studies are recruiting a combined 312 participants across the United States. Research is being conducted by 3 organizations including University of Alabama at Birmingham, Recursion Pharmaceuticals Inc., Healx Limited.
2026 Neurofibromatosis Research Landscape
As of March 2026, the neurofibromatosis clinical trial landscape includes 3 actively recruiting studies across 15 cities in the United States. These studies are collectively seeking 312 participants, with an average enrollment target of 104 per study.
Research is being led by 3 different organizations, including University of Alabama at Birmingham, Recursion Pharmaceuticals Inc., Healx Limited.
Geographically, neurofibromatosis trials are most concentrated in Los Angeles, California (3 trials); Birmingham, Alabama (2 trials); Cincinnati, Ohio (2 trials); Philadelphia, Pennsylvania (2 trials); Washington D.C., District of Columbia (2 trials) and 7 other cities.
Featured Neurofibromatosis Studies
Highlighted recruiting studies for neurofibromatosis, selected by enrollment size and research scope.
Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
Plexiform neurofibromas (PN) are known to cause significant morbidity in children with NF1. The recent FDA approval for selumetinib in children 2 years and older with inoperable symptomatic PN was based on the finding that selumetinib shrinks the majority of PN in children with NF1 and results in clinically meaningful benefit such as improvement in pain or range of motion. However, many morbiditie...
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
This is a two-staged, Phase 2/3, randomized, multi-center study to investigate the efficacy and safety of REC-2282 in patients with progressive NF2 mutated meningiomas.
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
The trial will be an open label, single arm, phase 2 study in 20 participants. The study will assess the tolerability and efficacy of HLX-1502 in participants with NF1 16 years of age or older with progressive and/or symptomatic PN.
Frequently Asked Questions About Neurofibromatosis Clinical Trials
Are there neurofibromatosis clinical trials near me?
Yes, there are 3 neurofibromatosis clinical trials currently recruiting across 15+ cities in the United States, including Los Angeles, California; Birmingham, Alabama; Cincinnati, Ohio. Browse the studies above to find one at a location convenient for you.
How do I join a neurofibromatosis clinical trial?
To join a neurofibromatosis clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are neurofibromatosis clinical trials free?
Yes, participation in neurofibromatosis clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of neurofibromatosis treatments are being studied?
Current neurofibromatosis clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 3 research organizations.
Is it safe to participate in neurofibromatosis clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov